---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-004415"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2024-06-21T23:59:59+00:00"
generated_at: "2026-06-01T02:50:14.964679+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xenetic appoints Parslow Interim CEO at $400k salary, $100k retention bonus; separations with former CEO/CSO

## Summary
- James Parslow appointed Interim CEO effective May 16, 2024; base salary increased to $400,000.
- Parslow eligible for $100,000 cash retention bonus if employed for ten months; receives option for 20,000 shares.
- Confidential separation agreements with former CEO Jeffrey Eisenberg and former CSO Curtis Lockshin providing severance per existing agreements.
- Eisenberg Separation Agreement includes accelerated vesting of all unvested stock options as of May 16, 2024.
- Stock option grant vests 1/4 on grant date and 1/4 on each of first three anniversaries, subject to continued employment.

## SEC filing metadata
- accession: 0001683168-24-004415
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2024-06-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316824004415/0001683168-24-004415-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316824004415/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-004415
- JSON: https://secwatch.observer/filing/0001683168-24-004415.json
- Plain text: https://secwatch.observer/filing/0001683168-24-004415.txt

## Key facts
- Executive change
  Curtis Lockshin departed as Chief Scientific Officer at Xenetic Biosciences, Inc..
  - Role: Chief Scientific Officer
  source text: and Curtis Lockshin, the Company’s former Chief Scientific Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534525/000168316824004415/0001683168-24-004415-index.htm
- Executive change
  Jeffrey F. Eisenberg departed as Chief Executive Officer at Xenetic Biosciences, Inc..
  - Role: Chief Executive Officer
  source text: the Company entered into a confidential separation agreement and general release with each of and Jeffrey F. Eisenberg, the Company’s former Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534525/000168316824004415/0001683168-24-004415-index.htm
- Executive change
  James F. Parslow was appointed as Interim Chief Executive Officer at Xenetic Biosciences, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: the Board of Directors of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534525/000168316824004415/0001683168-24-004415-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.